Skip to main content

Table 1 Patient and tumor characteristics according to the addition of bevacizumab to first-line systemic therapy (n = 361)

From: Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice

N = 361

Without bevacizumab (n = 176)

With bevacizumab (n = 185)

 

Combination chemotherapy (n = 219)

Single-agent chemotherapy (n = 142)

 
 

N

(%)

N

(%)

P-value

N

(%)

N

(%)

P-value

Gender

    

0.69

    

0.33

 Male

75

(43)

72

(41)

 

126

(58)

89

(63)

 

 Female

101

(57)

113

(59)

 

93

(42)

53

(37)

Age (years)

    

<0.0001

    

<0.0001

  < 60

36

(20)

57

(31)

 

71

(32)

24

(17)

 

 60–75

91

(52)

111

(60)

 

128

(59)

72

(51)

  ≥ 75

49

(28)

17

(9)

 

20

(9)

46

(32)

Comorbidity

    

<0.001

    

<0.01

 No

50

(28)

81

(44)

 

38

(28)

91

(42)

 

 1 comorbid condition

49

(28)

56

(30)

 

36

(26)

66

(30)

  ≥ 2 comorbid conditions

63

(36)

33

(18)

 

52

(36)

44

(20)

 Unknown

14

(8)

15

(8)

 

14

(19)

18

(8)

Primary tumor localization

    

0.13

    

 Rectum

68

(39)

85

(46)

 

107

(49)

47

(33)

<0.01

 Colon

108

(61)

100

(54)

 

112

(51)

95

(67)

 

Adjuvant chemotherapy

    

0.34

    

<0.01

 No

103

(59)

100

(54)

 

137

(63)

67

(47)

 

 Yes

73

(41)

85

(46)

 

82

(37)

75

(53)

Time to metastases (years)

    

0.12

    

0.59

  < 1 year

57

(32)

43

(23)

 

57

(26)

42

(30)

 

 1–2 years

56

(32)

71

(38)

 

82

(37)

46

(32)

  ≥ 2 years

63

(36)

71

(38)

 

80

(37)

54

(38)

Period of diagnosis metastases

    

<0.01

    

0.81

 2005–2006

70

(40)

41

(22)

 

69

(31)

42

(30)

 

 2007–2008

57

(32)

78

(42)

 

83

(38)

52

(37)

 2009–2011

49

(28)

66

(36)

 

67

(31)

48

(34)

Number of organs affected

    

0.29

    

0.39

 1 organ

72

(41)

85

(46)

 

92

(42)

65

(46)

 

 2 organs

69

(39)

59

(32)

 

83

(38)

44

(31)

  ≥ 3 organs

35

(20)

41

(22)

 

44

(20)

33

(23)

First-line chemotherapy

    

<0.0001

     

 Single agent chemotherapy

110

(63)

32

(27)

     

 Combination chemotherapy

66

(37)

153

(83)

Bevacizumab

         

<0.0001

 Yes

     

153

(70)

32

(23)

 

 No

     

66

(30)

110

(77)